Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 95% Improvement Relative Risk Arora et al. Zinc for COVID-19 LATE TREATMENT Is late treatment with zinc beneficial for COVID-19? Retrospective study in India Lower progression with zinc (p=0.000077) Arora et al., J. Infection, doi:10.1016/j.jinf.2021.12.039 Favors zinc Favors control
Risk factors for Coronavirus disease-associated mucormycosis
Arora et al., Journal of Infection, doi:10.1016/j.jinf.2021.12.039
Arora et al., Risk factors for Coronavirus disease-associated mucormycosis, Journal of Infection, doi:10.1016/j.jinf.2021.12.039
Mar 2022   Source   PDF  
  All Studies   Meta
Retrospective 152 COVID-associated mucormycosis cases and 200 controls, showing lower risk of COVID-associated mucormycosis with zinc treatment.
risk of progression, 95.0% lower, OR 0.05, p < 0.001, case control OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Arora et al., 31 Mar 2022, retrospective, India, peer-reviewed, 34 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: Journal of Infection 84 (2022) 383–390 Contents lists available at ScienceDirect Journal of Infection journal homepage: Risk factors for Coronavirus disease-associated mucormycosis Umang Arora a, Megha Priyadarshi a, Varidh Katiyar b, Manish Soneja a, Prerna Garg a, Ishan Gupta a, Vishwesh Bharadiya a, Parul Berry a, Tamoghna Ghosh a, Lajjaben Patel a, Radhika Sarda a, Shreya Garg c, Shubham Agarwal a, Veronica Arora d, Aishwarya Ramprasad a, Amit Kumar a, Rohit Kumar Garg a, Parul Kodan a, Neeraj Nischal a, Gagandeep Singh e, Pankaj Jorwal a, Arvind Kumar a, Upendra Baitha a, Ved Prakash Meena a, Animesh Ray a, Prayas Sethi a, Immaculata Xess e, Naval Vikram a, Sanjeev Sinha a, Ashutosh Biswas a, Alok Thakar c, Sushma Bhatnagar f, Anjan Trikha g, Naveet Wig a,∗ a Department of Medicine, AIIMS, Delhi, India Department of Neurosurgery, AIIMS, Delhi, India c Department of Otolaryngology & Head-Neck Surgery, AIIMS, Delhi, India d Department of Medical Genetics, Sir Ganga Ram Hospital, Delhi, India e Department of Microbiology, AIIMS, Delhi, India f Department of Onco-anaesthesia and Palliative Medicine, AIIMS, Delhi, India g Department of Anaesthesiology, Pain Medicine and Critical Care, AIIMS, Delhi, India b a r t i c l e i n f o Article history: Accepted 27 December 2021 Available online 30 December 2021 Keywords: Mucormycosis COVID-19 Risk factors Case control s u m m a r y Background: The epidemiology of the Coronavirus-disease associated mucormycosis (CAM) syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies. Methods: We performed a case-control study comparing cases diagnosed with CAM and taking controls as recovered COVID 19 patients who did not develop mucormycosis. Information on comorbidities, glycemic control, and practices related to COVID-19 prevention and treatment was recorded. Multivariate regression analysis was used to identify independent predictors. Results: A total of 352 patients (152 cases and 200 controls) diagnosed with COVID-19 during April-May 2021 were included. In the CAM group, symptoms of mucormycosis began a mean of 18.9 (SD 9.1) days after onset of COVID-19, and predominantly rhino-sinus and orbital involvement was present. All, but one, CAM cases had conventional risk factors of diabetes and steroid use. On multivariable regression, increased odds of CAM were associated with the presence of diabetes (adjusted OR 3.5, 95% CI 1.1–11), use of systemic steroids (aOR 7.7, 95% CI 2.4–24.7), prolonged use of cloth and surgical masks (vs. no mask, aOR 6.9, 95%CI 1.5–33.1), and repeated nasopharyngeal swab testing during the COVID-19 illness (aOR 1.6, 95% CI 1.2–2.2). Zinc therapy was found to be protective (aOR 0.05, 95%CI 0.01–0.19). Notably, the requirement of oxygen supplementation or hospitalization did not affect the risk of CAM. Conclusion: Judicious use of steroids and stringent glycemic control are vital to preventing mucormycosis. Use of clean masks, preference for N95 masks if available, and minimizing swab testing after the diagnosis of COVID-19 may further reduce the incidence of CAM. © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop